These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12941143)

  • 1. Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.
    Oh KS; Kweon MH; Rhee KH; Ho Lee K; Sung HC
    Immunology; 2003 Sep; 110(1):73-9. PubMed ID: 12941143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2.
    Inal JM; Schifferli JA
    J Immunol; 2002 May; 168(10):5213-21. PubMed ID: 11994478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2.
    Inal JM; Sim RB
    FEBS Lett; 2000 Mar; 470(2):131-4. PubMed ID: 10734221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor.
    Inal JM; Hui KM; Miot S; Lange S; Ramirez MI; Schneider B; Krueger G; Schifferli JA
    J Immunol; 2005 Jan; 174(1):356-66. PubMed ID: 15611259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.
    Hui KM; Orriss GL; Schirmer T; Magnadóttir B; Schifferli JA; Inal JM
    Biochem J; 2005 Aug; 389(Pt 3):863-8. PubMed ID: 15823096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice.
    Inal JM; Schneider B; Armanini M; Schifferli JA
    J Immunol; 2003 Apr; 170(8):4310-7. PubMed ID: 12682267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and purification of the anticomplementary peptide Sh-CRIT-ed1 (formerly Sh-TOR-ed1) as a tetramultimer in Escherichia coli.
    Oh KS; Na DK; Kweon MH; Sung HC
    Protein Expr Purif; 2003 Feb; 27(2):202-9. PubMed ID: 12597878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRIT peptide interacts with factor B and interferes with alternative pathway activation.
    Hui KM; Magnadóttir B; Schifferli JA; Inal JM
    Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.
    Woehl JL; Stapels DAC; Garcia BL; Ramyar KX; Keightley A; Ruyken M; Syriga M; Sfyroera G; Weber AB; Zolkiewski M; Ricklin D; Lambris JD; Rooijakkers SHM; Geisbrecht BV
    J Immunol; 2014 Dec; 193(12):6161-6171. PubMed ID: 25381436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Carbohydrate-linked Phosphorylcholine of the Parasitic Nematode Product ES-62 Modulates Complement Activation.
    Ahmed UK; Maller NC; Iqbal AJ; Al-Riyami L; Harnett W; Raynes JG
    J Biol Chem; 2016 May; 291(22):11939-53. PubMed ID: 27044740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The purification and properties of the second component of guinea-pig complement.
    Kerr MA; Gagnon J
    Biochem J; 1982 Jul; 205(1):59-67. PubMed ID: 6922702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement C2 receptor inhibitor trispanning: from man to schistosome.
    Inal JM
    Springer Semin Immunopathol; 2005 Nov; 27(3):320-31. PubMed ID: 16235057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi.
    Cestari Idos S; Krarup A; Sim RB; Inal JM; Ramirez MI
    Mol Immunol; 2009 Dec; 47(2-3):426-37. PubMed ID: 19783051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
    Kerr MA; Parkes C
    Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.